Navigation Links
BioCryst Provides Update Regarding Peramivir for Influenza
Date:9/30/2009

sh burn rate may not be consistent with our expectations; that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

SOURCE BioCryst Pharmaceuticals, Inc.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
2. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
3. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
4. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
5. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
6. BioCryst Updates Peramivir Clinical Development Plan
7. BioCryst Provides Forodesine HCl Update
8. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
9. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
10. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
11. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 Research and ... the "Future Horizons and Growth Strategies in ... and Country Forecasts" report to their offering. ... the European Blood Banking Market 2015 is a ... current suppliers and potential market entrants identify and ...
(Date:7/1/2015)... July 1, 2015  Celsion Corporation (NASDAQ: CLSN ... Michael H. Tardugno , Chairman, President and CEO, ... Healthcare Conference on Wednesday, July 8, 2015, at 4:15 ... Parker Meridien Hotel located at 119 W. 56th Street, ... A copy of the presentation will be available ...
(Date:7/1/2015)... (Continental) announced it is expanding its Baltimore -based clinical studies network and ... for unique patient populations.  Photo - ... ... ... "Continental hosts clinical studies for physicians ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 3Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 4
(Date:7/2/2015)... ... July 02, 2015 , ... ... their products, services, channels and business models. To help manage the increasing demand ... addition of Mark Benkendorf as SVP of Strategic Engagements. , Benkendorf is a ...
(Date:7/1/2015)... ... 2015 , ... In the United States, summer has always been the season ... Arabia and Dubai, the summer temperatures are so hot, that July vacationers often leave ... Saleh of ORA Dentistry Spa notes that a trip to the United States, and ...
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. ... Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and ... therapeutics against middle-ear infections. , The grant from the National Institute on Deafness ...
(Date:7/1/2015)... ... July 01, 2015 , ... The federal court overseeing a ... has granted the Defendants’ Motion for Summary Judgment. According to an Order issued ... the Court rejected the Plaintiff’s assertion that one manufacturer can be held ...
(Date:7/1/2015)... ... July 01, 2015 , ... There ... liberty. Americans have been arguing over laws governing sexuality since the first Pilgrims ... a forthcoming historical comparative biography by Cindy Safronoff reveals. Crossing Swords: Mary Baker ...
Breaking Medicine News(10 mins):Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 2Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 4
... , , DALLAS, Sept. 11 ... (OTC Bulletin Board: ACCP) has entered into an agreement with ... distribution. One or more U.S. market seeding studies could begin as ... In a comparison of cancer patients receiving standard oral mucositis care with ...
... NEW YORK, Sept. 11 The NY Chiropractic ... ("PCA"), the Association of New Jersey Chiropractors ("ANJC"), fourteen ... have sued as the class representatives of the putative class. ... Gross LLP and co-counsel Buttaci & Leardi, LLC, have filed ...
... heavy traffic noise had raised readings , FRIDAY, Sept. ... be bad for your blood pressure, a new study suggests. ... horns honking and brakes screeching have an increased risk of ... of Environmental Health . , A team from Lund ...
... study has found that two genes in mice were associated ... These findings give researchers new hope for developing more effective ... outcomes. This study will be presented at the Congress of ... in Dusseldorf, Germany, on Sept. 11, 2009. "Most ...
... , CUPERTINO, Calif., Sept. 11 ... reported that it has entered into a privately negotiated transaction ... of Venrock at a price of $2.25 per share, raising ... expects the financing to close on or about September 18, ...
... DUBLIN, Ohio, Sept. 11 Cardinal Health today announced the ... to purchase up to an aggregate purchase price of $1.2 billion ... tender offer is part of a previously announced plan to reduce ... of CareFusion Corp. and includes notes issued by both Cardinal Health ...
Cached Medicine News:Health News:Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States 2Health News:Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States 3Health News:Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States 4Health News:Blue Cross and Blue Shield Sued by Health Care Providers for Abusive Practices 2Health News:Blue Cross and Blue Shield Sued by Health Care Providers for Abusive Practices 3Health News:Busy Roads Boost Blood Pressure 2Health News:Mayo Clinic identifies 2 genes as potential therapeutic targets for multiple sclerosis 2Health News:DURECT Announces Sale of 4,444,444 Shares of Common Stock, Raising Proceeds of $10 Million 2Health News:Cardinal Health Announces Early Tender Results of Debt Tender Offer 2Health News:Cardinal Health Announces Early Tender Results of Debt Tender Offer 3Health News:Cardinal Health Announces Early Tender Results of Debt Tender Offer 4Health News:Cardinal Health Announces Early Tender Results of Debt Tender Offer 5Health News:Cardinal Health Announces Early Tender Results of Debt Tender Offer 6
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders....
This probe coagulates bleeders while suction channel with trumpet valve simultaneously evacuates smoke....
Medicine Products: